Targeting glucose metabolism and metabolic vulnerabilities, such as gfat1 and acss2, may play a potential role in delaying bladder cancer tumor progression and improving chemotherapy resistance. This evidence concerns the gene ACSS2 and urinary bladder carcinoma.